Terumo Corporation · TSE:4543
Terumo — Investor Presentation (May 2025)
19 slides from Terumo's investor presentation, May 14, 2025
Slide 1: GS26 Mid-term Review & Taking on the Challenge of Global CDMO
GS26 Mid-term Review & Taking on the Challenge of Global CDMO May 14, 2025 Terumo Corporation Chief Executive Officer Hikaru Samejima
Slide 2: Forward-Looking Statements and Use of Document
Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performanc
Slide 3: Progress against GS26 Financial Targets (3rd Year) and Forecast
Progress against GS26 Financial Targets (3rd Year) and Forecast 3-year CAGR: 15.2% 7.5% 14% (7%) (17.5% excluding one- time expenses) Sales CAGR in parentheses is calculated based on the assumed exchange rate at the time of GS26's announcement. Progress toward GS26 is generally favorable, and demand
Slide 4: Trends and Factors Affecting Changes in Operating Profit Margin
Trends and Factors Affecting Changes in Operating Profit Margin Major breakdown of -1.3 pt (FY21➝FY24) 22.00% +2.3pt Business expansion (including various 20.0% measures) OP amount OP% 20.00% +0.3pt Foreign exchange 18.5% -1.8 pt Inflationary effects (100M JPY) 17.5% 18.00% -2.3 pt One-time expenses
Slide 5: GS26 3rd Year Review (Company-wide)
GS26 3rd Year Review (Company-wide) GS26 Target Sales: Annual growth in the high single-digit Sales 3-year CAGR Profit: 20% 14% (7%) Three-Year Results FY24 OP% fell due to one-time expenses, but AOP improved significantly due to the favorable business environment 20% Innovation • Visualizat
Slide 6: GS26 3rd Year Review (C&V)
GS26 3rd Year Review (C&V) GS26 Target Sales: Annual growth in the high single-digit Sales 3-year CAGR AOP: 2% points improvement 16% (7%) Three-Year Results Expand therapeutic business through new 2pt up product launches Production transfer, promotion of smart factories Drive radial proce
Slide 7: GS26 3rd Year Review (TMCS)
GS26 3rd Year Review (TMCS) GS26 Target Sales: Annual growth in the mid single-digit Sales 3-year CAGR AOP: 15% 4% (2%) Three-Year Results V-shaped recovery in business performance through counter-measures to the deteriorating external environment (pricing & cost reduction measures) Provide
Slide 8: GS26 3rd Year Review (TBCT)
GS26 3rd Year Review (TBCT) GS26 Target Sales Sales: Near double-digit growth 3-year CAGR AOP: 20% 18% (11%) Three-Year Results Accelerate Rika's expansion and attract new customers 20% Pursuit of stable profits through supply system reforms • Optimization of production sites • Logistics res
Slide 9: GS26 3rd Year Review (TBCT) *Excluding exchange rate effects
GS26 3rd Year Review (TBCT) *Excluding exchange rate effects GS26 Target Sales: Near double-digit growth Sales 3-year CAGR AOP: 20% 11% Three-Year Results Accelerate Rika's expansion and attract new customers 20% Pursuit of stable profits through supply system reforms • Optimization of produ
Slide 10: "From Devices to Solutions" (Mid- to Long-Term Vision)
"From Devices to Solutions" (Mid- to Long-Term Vision) 01 02 03 Delivery Digital Deviceuticals TM ©TERUMO CORPORATION 10 / 18
Slide 11: Terumo CDMO's Unique Business Model
Terumo CDMO’s Unique Business Model General CDMO (Division of Labor) ・Pharmaceutical companies need individual contracts for each process ・Collaboration and problem solving beyond the scope of the process they are in charge of become more difficult ・Partner with pharmaceutical companies from the ear
Slide 12: Terumo CDMO's Strengths
Terumo CDMO’s Strengths While being a medical device manufacturer with a comprehensive understanding of devices, More than 50 years of experience in handling pharmaceuticals makes this possible, Development of innovative drug delivery devices suitable for drug characteristics Drug Formulation Clinic
Slide 13: Terumo CDMO's Development Capability = Built-up Technologies
Terumo CDMO’s Development Capability = Built-up Technologies CDMO Biopharmaceuticals Hardware (Main equipment) Technology for developing painless injection needles and tubes ME Pump3... Development design and assembly technology for precision equipment Disposables PFS2 ... Coating technology, asepti
Slide 14: Terumo CDMO's Solutions: Drugs x Device
Terumo CDMO's Solutions Pharmaceutical companies Drugs x Device Developing drug Maximizing the value of delivery methods pharmaceutical products ©TERUMO CORPORATION 14 / 18
Slide 15: On-body Injector that Embodies the Deviceuticals Concept
On-body Injector that Embodies the DeviceuticalsTM Concept Issue Challenges • Burden of patient's travel to hospital, shortage of • Reduced patient burden (pain during injection, smaller healthcare professionals and workload and lighter device) • Reliable automatic administration of drugs at schedul
Slide 16: CDMO Market and Terumo's Sales Growth
CDMO Market and Terumo's Sales Growth Market growth rate Expansion of the Terumo CDMO business High is outpacing market growth Formulation and filling CAGR $12,000M 11% Administration device manufacture CAGR $1,900M 7% Needle bundled with Drug $300M FY17 CAGR FY24 FY26 6% FY3X Low Reference: Terumo
Slide 17: Terumo CDMO's Strategy
Terumo CDMO’s Strategy Differentiated business model based on strengths Establishment of a planned production system Scheduled to be completed in September 2025 more than quadrupled FY17 FY24 FY3X 2023 Production line expansion ©TERUMO CORPORATION 17 / 18
Slide 18: Becoming a Leading CDMO Company
Becoming a Leading CDMO Company Leverkusen, Germany • Significantly reduced start-up time for a European site • Acquire cutting-edge assets as well as highly specialized human resources • Direct communication with customers to drive business forward Acquisition of European production facilities Esta
Slide 19: ~“TERUMO
~“TERUMO